AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35174419 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate 5-day peer support training
Number of subjects: 100
Study 35174419 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 100
Study 33624821 — intervention group
Group type: EXPERIMENTAL
Intervention: Regions with winter holiday exclusively in week 9
Number of subjects: 219
Study 33624821 — intervention group
Group type: COMPARATOR
Intervention: More stringent government response implemented in week 11
Number of subjects: 219
Study 34689128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation for 60 days
Number of subjects: 74
Study 33942343 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection of 10 mg nalbuphine
Number of subjects: 20
Study 33942343 — intervention group
Group type: COMPARATOR
Intervention: PCA-mimic method of 10 mg nalbuphine (2 mg once for five times with a 30-min interval)
Number of subjects: 20
Study 32423734 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic Echocardiography (TTE)
Number of subjects: 25
Study 32423734 — intervention group
Group type: COMPARATOR
Intervention: Transesophageal Echocardiography (TEE)
Number of subjects: 25
Study 32423734 — intervention group
Group type: COMPARATOR
Intervention: Modified deep transgastric view (TEE)
Number of subjects: 25
Study 32423734 — intervention group
Group type: COMPARATOR
Intervention: Transgastric right ventricular inflow view (TEE)
Number of subjects: 25
Study 32423734 — intervention group
Group type: EXPERIMENTAL
Intervention: Speckle tracking TAPSE (TEE)
Number of subjects: 25
Study 32423734 — intervention group
Group type: COMPARATOR
Intervention: Speckle tracking TAPSE (TTE)
Number of subjects: 25
Study 35378301 — intervention group
Group type: EXPERIMENTAL
Intervention: EVO intervention (online lessons, smartphone app for self-monitoring, 12 brief calls with a Health Promotionist)
Number of subjects: 524
Study 35378301 — intervention group
Group type: COMPARATOR
Intervention: DPP intervention (first 6 months of CDC's T2D materials, 16 one-hour video call sessions with certified staff)
Number of subjects: 524
Study 35378301 — intervention group
Group type: EXPERIMENTAL
Intervention: EVO
Number of subjects: 524
Study 35378301 — intervention group
Group type: COMPARATOR
Intervention: DPP
Number of subjects: 524
Study 34504336 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (500 ml)
Number of subjects: 940
Study 34504336 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 940
Study 32753300 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 36
Study 32753300 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 36
Study 36167537 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental hemodialysis (twice-weekly for 6 weeks followed by thrice-weekly)
Number of subjects: 20
Study 36167537 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (thrice-weekly)
Number of subjects: 20
Study 34038706 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 100
Study 34038706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 34048435 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured small-group student talk as collaborative prewriting discussions
Number of subjects: 0
Study 34048435 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no structured small-group discussions)
Number of subjects: 0
Study 34365883 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame-training (home-based X-box One Kinect training focused on balance for 6-8 weeks)
Number of subjects: 35
Study 34365883 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 35
Study 34256795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor rehabilitation (1 pre-rehabilitation session and 9 to 12 sessions including patient education, pelvic floor muscle exercises, pelvic floor electromyography biofeedback, and capacitive and sensory rectal training with a balloon probe)
Number of subjects: 56
Study 34256795 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 56
Study 35325620 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNO alone
Number of subjects: 299
Study 35325620 — intervention group
Group type: COMPARATOR
Intervention: NIV alternating with HFNO
Number of subjects: 299
Study 33492083 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal ratio ventilation (ERV) with I:E ratio of 1:1
Number of subjects: 28
Study 33492083 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation with I:E ratio of 1:2
Number of subjects: 28
Study 34296549 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Automatic Massage (EAM)
Number of subjects: 0
Study 34296549 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32070400 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized high PEEP with recruitment maneuvers (RM)
Number of subjects: 1468
Study 32070400 — intervention group
Group type: COMPARATOR
Intervention: Low PEEP (5 cm H2O without RM)
Number of subjects: 1468
Study 36152744 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA)
Number of subjects: 22
Study 36152744 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 22
Study 33468271 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberry (24 g/d for 90 days)
Number of subjects: 37
Study 33468271 — intervention group
Group type: COMPARATOR
Intervention: SB placebo
Number of subjects: 37
Study 32428636 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy
Number of subjects: 60
Study 32428636 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 60
Study 32428636 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy & Massage
Number of subjects: 60
Study 35709650 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin Glycinate (MG) treatment
Number of subjects: 0
Study 35709650 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33638230 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a face mask
Number of subjects: 527
Study 33638230 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing/hand sanitising
Number of subjects: 527
Study 33638230 — intervention group
Group type: EXPERIMENTAL
Intervention: Social distancing
Number of subjects: 527
Study 32384947 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-albumin paclitaxel combined with cisplatin
Number of subjects: 78
Study 32384947 — intervention group
Group type: COMPARATOR
Intervention: Traditional paclitaxel combined with cisplatin
Number of subjects: 78
Study 34256828 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support intervention (DESI) for primary endocrine therapy (PET) or surgery with adjuvant therapies
Number of subjects: 1339
Study 34256828 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support intervention (DESI) for adjuvant chemotherapy after surgery
Number of subjects: 1339
Study 34256828 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1339
Study 34256828 — intervention group
Group type: EXPERIMENTAL
Intervention: Online risk prediction model and brief decision aid
Number of subjects: 1339
Study 34256828 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support intervention (DESI)
Number of subjects: 1339
Study 33156760 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomass fuel use
Number of subjects: 1705
Study 33156760 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to toxic gases
Number of subjects: 1705
Study 33156760 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >40 years
Number of subjects: 1705
Study 35894958 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 3 mg/kg body mass
Number of subjects: 8
Study 35894958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 33914729 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 3041
Study 33914729 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine (IIV)
Number of subjects: 3041
Study 33914729 — intervention group
Group type: COMPARATOR
Intervention: Control (Nasal placebo and IPV)
Number of subjects: 3041
Study 36350066 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-delivered CBT (6, 8, or 12 weekly sessions) augmented with a CBT skills practice smartphone application
Number of subjects: 12
Study 36350066 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) T2DM care
Number of subjects: 12
Study 33939452 — intervention group
Group type: EXPERIMENTAL
Intervention: AFVP + IPS‐SE
Number of subjects: 84
Study 33939452 — intervention group
Group type: COMPARATOR
Intervention: AFVP
Number of subjects: 84
Study 32277514 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (reading an article)
Number of subjects: 138
Study 32277514 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (watching an educational video)
Number of subjects: 138
Study 32277514 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (viewing a PowerPoint presentation)
Number of subjects: 138
Study 32277514 — intervention group
Group type: COMPARATOR
Intervention: Initial survey (before intervention)
Number of subjects: 138
Study 34997360 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + thermosensitive gel containing 0.8% oligo hyaluronic acid and octenidine HCl 0.625%
Number of subjects: 34
Study 34997360 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 34
Study 33624945 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model
Number of subjects: 270
Study 33624945 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost model
Number of subjects: 270
Study 32811715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 799
Study 32811715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 799
Study 35975643 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.247% ropivacaine in 20 mL for ACB and IPACK block
Number of subjects: 52
Study 35975643 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful block (n = 45)
Number of subjects: 52
Study 35975643 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed block (n = 7)
Number of subjects: 52
Study 34440942 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive multimodal Brain-Computer Interfacing-Virtual Reality (BCI-VR) training after bilateral neuromodulation with rTMS
Number of subjects: 42
Study 34440942 — intervention group
Group type: COMPARATOR
Intervention: Neuromodulation combined with conventional motor imagery tasks
Number of subjects: 42
Study 33511604 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile stroke units (MSU)
Number of subjects: 0
Study 33511604 — intervention group
Group type: COMPARATOR
Intervention: Standard emergency room treatment
Number of subjects: 0
Study 33511604 — intervention group
Group type: COMPARATOR
Intervention: Standard ambulance and hospital treatment
Number of subjects: 0
Study 36072939 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxemia (target PaO2 200 – 250 mmHg)
Number of subjects: 15
Study 36072939 — intervention group
Group type: COMPARATOR
Intervention: Normoxemia (target PaO2 80 – 120 mmHg)
Number of subjects: 15
Study 36072939 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxemia
Number of subjects: 15
Study 33367229 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA administration in the 12-14 mm group
Number of subjects: 29
Study 33367229 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA administration in the 15-17 mm group
Number of subjects: 29
Study 33367229 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA administration in the ≥ 18 mm group
Number of subjects: 29
Study 33367229 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA overall effect on ovulation
Number of subjects: 29
Study 33367229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-DMPA LH concentrations
Number of subjects: 29
Study 33367229 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h MPA concentrations post-DMPA administration
Number of subjects: 29
Study 32407608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 8232
Study 32407608 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8232
Study 35759476 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behavioural therapy (CBT) plus social participation program
Number of subjects: 172
Study 35759476 — intervention group
Group type: COMPARATOR
Intervention: Standard CBT
Number of subjects: 172
Study 33089545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle weight loss interventions
Number of subjects: 242
Study 33296470 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Living Triple P (two, 2-hr group sessions delivered face-to-face or online)
Number of subjects: 17
Study 33827851 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-lying sleep positioning
Number of subjects: 244
Study 33827851 — intervention group
Group type: COMPARATOR
Intervention: Back-lying sleep positioning
Number of subjects: 244
Study 32386474 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS) pathway
Number of subjects: 196
Study 32386474 — intervention group
Group type: COMPARATOR
Intervention: Control group (historically matched)
Number of subjects: 196
Study 35186761 — intervention group
Group type: EXPERIMENTAL
Intervention: aBVA procedure
Number of subjects: 60
Study 35186761 — intervention group
Group type: COMPARATOR
Intervention: VAB procedure
Number of subjects: 60
Study 34886868 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one, on-site clinical mentorship for 8 hours a week, every 6 weeks over 9 months
Number of subjects: 0
Study 34886868 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 34886868 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one, on-site clinical mentorship
Number of subjects: 0
Study 33179268 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge within 28 hours after cesarean section with a home visit by a midwife the following day
Number of subjects: 143
Study 33179268 — intervention group
Group type: COMPARATOR
Intervention: Standard care: Discharge after 48 hours following cesarean section
Number of subjects: 143
Study 32567233 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone combined with flurbiprofen axetil (OF)
Number of subjects: 133
Study 32567233 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil combined with flurbiprofen axetil (SF)
Number of subjects: 133
Study 36073583 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex therapy (standard treatment + cell therapy)
Number of subjects: 60
Study 36073583 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic surgical treatment
Number of subjects: 60
Study 34294090 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN-based segmentation software
Number of subjects: 470
Study 35781083 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse total shoulder arthroplasty (RTSA)
Number of subjects: 124
Study 35781083 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 124
Study 34296686 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-triggered breaths
Number of subjects: 40
Study 34296686 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe double-triggering group
Number of subjects: 40
Study 34296686 — intervention group
Group type: COMPARATOR
Intervention: Normal breaths (control)
Number of subjects: 40
Study 32906163 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention (multimodal strategy)
Number of subjects: 0
Study 32906163 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated voice prompts at disinfectant dispensers
Number of subjects: 0
Study 32906163 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-intervention period)
Number of subjects: 0
Study 34274552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting (IF)
Number of subjects: 46
Study 34274552 — intervention group
Group type: COMPARATOR
Intervention: Calorie Restriction (CR)
Number of subjects: 46
Study 32441544 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-reflection intervention
Number of subjects: 144
Study 32441544 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 144
Study 35879713 — intervention group
Group type: EXPERIMENTAL
Intervention: Short incision surgery
Number of subjects: 24
Study 35879713 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive surgery (MIS) with tool-kit
Number of subjects: 24
Study 34476726 — intervention group
Group type: EXPERIMENTAL
Intervention: VLRL-RYGB
Number of subjects: 444
Study 34476726 — intervention group
Group type: COMPARATOR
Intervention: S-LRYGB
Number of subjects: 444
Study 32106328 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenchymal RRI measurements
Number of subjects: 22
Study 32106328 — intervention group
Group type: EXPERIMENTAL
Intervention: Hilar RRI measurements
Number of subjects: 22
Study 32106328 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound machine type
Number of subjects: 22
Study 32106328 — intervention group
Group type: COMPARATOR
Intervention: Depth of kidney transplant
Number of subjects: 22
Study 34910859 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX‐CoV2373 vaccine
Number of subjects: 29949
Study 34910859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29949
Study 32366273 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCM arm counseling fidelity protocol
Number of subjects: 0
Study 32366273 — intervention group
Group type: EXPERIMENTAL
Intervention: CTTS counseling calls
Number of subjects: 0
Study 32366273 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing adherence coders
Number of subjects: 0
Study 32366273 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling modules
Number of subjects: 0
Study 32366273 — intervention group
Group type: EXPERIMENTAL
Intervention: CTTS monthly calls
Number of subjects: 0
Study 32366273 — intervention group
Group type: COMPARATOR
Intervention: eReferral arm counseling
Number of subjects: 0
Study 35076930 — intervention group
Group type: EXPERIMENTAL
Intervention: Various strategies to handle death during clinical trials for ALS
Number of subjects: 0
Study 35076930 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 33165918 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.5 mg (Group A)
Number of subjects: 64
Study 33165918 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (Group S)
Number of subjects: 64
Study 34383954 — intervention group
Group type: EXPERIMENTAL
Intervention: verinurad + allopurinol
Number of subjects: 725
Study 34383954 — intervention group
Group type: COMPARATOR
Intervention: allopurinol
Number of subjects: 725
Study 34383954 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 725
Study 34564448 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet intervention
Number of subjects: 50
Study 34564448 — intervention group
Group type: COMPARATOR
Intervention: Western-style control diet
Number of subjects: 50
Study 35103539 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus 3cir‐OFF HAIC (400 mg sorafenib twice daily + 35 mg/m2 oxaliplatin followed by 600 mg/m2 5‐fluorouracil, days 1‐3)
Number of subjects: 64
Study 35103539 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib alone (400 mg twice daily)
Number of subjects: 64
Study 35103539 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus 3cir‐OFF HAIC
Number of subjects: 64
Study 34563982 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose aspirin (LDA) 60 mg
Number of subjects: 82
Study 34563982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 32954768 — intervention group
Group type: EXPERIMENTAL
Intervention: mPADSS scale intervention group
Number of subjects: 118
Study 32954768 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 118
Study 32954768 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study 32954768 — intervention group
Group type: EXPERIMENTAL
Intervention: mPADSS scale intervention group and Control group
Number of subjects: 118
Study 33944909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI)
Number of subjects: 144
Study 33338437 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg every other day for 12 weeks
Number of subjects: 695
Study 33338437 — intervention group
Group type: COMPARATOR
Intervention: Placebo every other day for 12 weeks
Number of subjects: 695
Study 33338437 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg
Number of subjects: 695
Study 33338437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 695
Study 33087170 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) intervention for 12 weeks
Number of subjects: 0
Study 33087170 — intervention group
Group type: COMPARATOR
Intervention: Stretching and toning (ST) control intervention for 12 weeks
Number of subjects: 0
Study 36450449 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour necrosis factor (TNF) inhibitor (TNFi)
Number of subjects: 115
Study 36450449 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (sulfasalazine and hydroxychloroquine)
Number of subjects: 115
Study 36450449 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TNFi and triple therapy)
Number of subjects: 115
Study 34403606 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ three lifetime sexual partners
Number of subjects: 900
Study 34403606 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary school education
Number of subjects: 900
Study 34403606 — intervention group
Group type: EXPERIMENTAL
Intervention: Primigravida status
Number of subjects: 900
Study 34403606 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV screening and confirmatory tests
Number of subjects: 900